[Desmopressin: the treatment of primary nocturnal enuresis].
OBJECTIVE
The efficacy of desmopressin, a drug that reduces nocturnal urine volume with no side effects, was evaluated in a group of 21 patients.


METHODS
20 boys and 1 girl with primary nocturnal enuresis were treated with intranasal desmopressin (DDAVP) for a period of 12 weeks.


RESULTS
An improvement in 80.95% was achieved. Following treatment enuresis recurred, but to a lesser degree than before therapy.


CONCLUSIONS
DDAVP is useful in the treatment of primary nocturnal enuresis whose etiology is not organic or functional.
Granados
E A
EA
Unidad de Urología Pediátrica, Fundación Puigvert, Barcelona, España.
Garat
J M
JM
D000293:Adolescent; D002648:Child; D002908:Chronic Disease; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D004775:Enuresis / Q000188:drug therapy* / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D012008:Recurrence; D013997:Time Factors
D003894:Deamino Arginine Vasopressin
Desmopresina: el tratamiento en la enuresis nocturna primaria.